Skip to content
10-Q

Quarterly Report

Lomond Therapeutics Holdings, Inc.

0001213900-25-046033

← back to feed
Filed
May 20, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 13, 2025 32.2M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $10.07M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $37.65M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $28.42M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.69M
Current Liabilities Q1 2025 · Dec 31, 2024 $2.55M
Total Liabilities Q1 2025 · Mar 31, 2025 $12.69M
Total Liabilities Q1 2025 · Dec 31, 2024 $5.5M
Current Assets Q1 2025 · Mar 31, 2025 $49.29M
Current Assets Q1 2025 · Dec 31, 2024 $29.25M
Total Assets Q1 2025 · Mar 31, 2025 $49.29M
Total Assets Q1 2025 · Dec 31, 2024 $29.25M
Shares Diluted restated Q1 2025 · Mar 31, 2024 758.97K sh
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$131.26K
Stockholders Equity restated Q1 2025 · Mar 31, 2024 −$5.65M
Stockholders Equity restated Q1 2025 · Dec 31, 2023 −$5.52M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.20
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.20
Sga Expense restated Q1 2025 · Mar 31, 2024 $143.86K
Rd Expense Q1 2025 · Mar 31, 2024 $7.81K
Net Income restated Q1 2025 · Mar 31, 2024 −$151.68K
Operating Income restated Q1 2025 · Mar 31, 2024 −$151.68K